Screener
Fulgent Genetics, Inc. FLGT Therapeutic Development — Finite Lived Intangible Assets Net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Weighted-Average Amortization Period | March 31, 2026 | December 31, 2025 |
|---|---|---|---|
| Total | 83,295 | 62,555 | |
| Therapeutic Development | |||
| Customer relationships | 18 Years | 2,300 | 2,300 |
| Less: accumulated amortization | (96) | (64) | |
| Customer relationships, net | 2,204 | 2,236 | |
| In-process research & development | n/a | 68,490 | 68,490 |
| Total | 70,694 | 70,726 | |
| Total intangible assets, net | $153,989 | $133,281 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s therapeutic development — finite lived intangible assets net?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — finite lived intangible assets net of $70.69M in Q1 2026.
- What does therapeutic development — finite lived intangible assets net mean?
- The remaining unamortized book value of identifiable intangible assets held by the therapeutic development segment. This value represents the current carrying amount of the segment's core intellectual property and technological assets.
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — finite lived intangible assets net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude